scispace - formally typeset
S

Sivanandhan Dhanalakshmi

Researcher at Anschutz Medical Campus

Publications -  31
Citations -  2432

Sivanandhan Dhanalakshmi is an academic researcher from Anschutz Medical Campus. The author has contributed to research in topics: Silibinin & Apoptosis. The author has an hindex of 23, co-authored 28 publications receiving 2339 citations.

Papers
More filters
Journal ArticleDOI

Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.

TL;DR: The results identify molecular mechanisms of silibinin efficacy as a cell cycle regulator and apoptosis inducer in human colon carcinoma HT-29 cells, and justify further studies to investigate potential usefulness of this nontoxic agent in colon cancer prevention and intervention.
Journal Article

Dietary Feeding of Silibinin Inhibits Advance Human Prostate Carcinoma Growth in Athymic Nude Mice and Increases Plasma Insulin-like Growth Factor-binding Protein-3 Levels

TL;DR: These findings extend and translate the observations on in vitro anticancer effect of silibinin/silymarin to an in vivo preclinical PCA model, which may form the basis for a Phase I clinical trial in PCA patients.
Journal ArticleDOI

Grape seed extract inhibits advanced human prostate tumor growth and angiogenesis and upregulates insulin-like growth factor binding protein-3.

TL;DR: The findings suggest that GSE possesses in vivo anticancer efficacy against hormone‐refractory human PCA, which is associated with its antiproliferative, proapoptotic and antiangiogenic activities together with upregulation of IGFBP‐3.
Journal ArticleDOI

Phytochemicals as cell cycle modulators--a less toxic approach in halting human cancers.

TL;DR: The present review is focused on the modulatory effects of phytochemicals on critical cell cycle molecules, and discusses how they inhibit proliferation and/or induce apoptotic death in cancer cells.
Journal ArticleDOI

Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis.

TL;DR: Results indicate that silibinin could be used to enhance the effectiveness of TNF α-based chemotherapy in advanced PCA and inhibits TNFα-induced activation of NF-κB via IκBα pathway and subsequently sensitizes DU145 cells to TNFβ-induced apoptosis.